Despite outstanding clinical science, Europe has historically lagged behind the US, if not in medical device innovation, at least in device company creation. A vicious cycle of few start-ups, reluctant VCs, and a poor pool of experienced managers has kept company creation from exploding. But now former merchant bankers turned serial entrepreneurs, Herb Oakes and Dick Lyman, believe they have a better formula for starting device companies in Europe.
Successful device-company creation works in a kind of virtuous circle: physicians or engineers with promising ideas find venture backers who believe in those ideas and fund the launch of a company to bring the innovation to market and who, in turn, after a certain period of time, find seasoned executives to grow the company and realize the potential of the idea.
But that virtuous circle can turn vicious if any of those pieces are missing: if physicians are reluctant to commercialize...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
